Human T2R38 bitter taste receptor expression and Covid-19 : from immunity to prognosis
Bethineedi, Lakshmi Deepak Baghsheikhi, Hediyeh Soltani, Afsaneh Mafi, Zahedeh Samieefar, Noosha Sanjid Seraj, Shaikh Khazeei Tabari, Mohammad Amin
Bethineedi, Lakshmi Deepak
Baghsheikhi, Hediyeh
Soltani, Afsaneh
Mafi, Zahedeh
Samieefar, Noosha
Sanjid Seraj, Shaikh
Khazeei Tabari, Mohammad Amin
Abstract
Bitter taste-sensing type 2 receptor (T2Rs or TAS2Rs) found on ciliated epithelial cells and solitary chemosensory cells have a role in respiratory tract immunity. T2Rs have shown protection against SARS-CoV-2 by enhancing the innate immune response. The purpose of this review is to outline the current sphere of knowledge regarding this association.
Methods:
A narrative review of the literature was done by searching (T2R38 OR bitter taste receptor) AND (COVID-19 OR SARS-CoV-2) keywords in PubMed and google scholar.
Results:
T2R38, an isoform of T2Rs encoded by the TAS2R38 gene, may have a potential association between phenotypic expression of T2R38 and prognosis of COVID-19. Current studies suggest that due to different genotypes and widespread distributions of T2Rs within the respiratory tract and their role in innate immunity, treatment protocols for COVID-19 and other respiratory diseases may change accordingly. Based on the phenotypic expression of T2R38, it varies in innate immunity and host response to respiratory infection, systemic symptoms and hospitalization.
Conclusion:
This review reveals that patients' innate immune response to SARS-COV-2 could be influenced by T2R38 receptor allelic variations.
MIDER Authors
Citations
Altmetric:
Date
2023-04
Type
Article
Subject
Communicable diseases
Collections
Citation
Bethineedi LD, Baghsheikhi H, Soltani A, Mafi Z, Samieefar N, Sanjid Seraj S, Khazeei Tabari MA. Human T2R38 Bitter Taste Receptor Expression and COVID-19: From Immunity to Prognosis. Avicenna J Med Biotechnol. 2023 Apr-Jun;15(2):118-123. PMID: 37034895; PMCID: PMC10073923.
Journal / Source Title
Avicenna Journal of Medical Biotechnology
DOI
PMID
37034895
Publisher
Avicenna Research Institute